June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Fibrosis and HRM changes in treated neovascular age-related macular degeneration: findings from multimodal imaging of the IVAN clinical trial
Author Affiliations & Notes
  • Luping Wang
    Centre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom
    Ophthalmology, Beijing Friendship Hospital, Captial Medical University, Beijing, China
  • Alyson Muldrew
    Centre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom
    University of Bonn, Bonn, Germany
  • Barney Reeves
    University of Bristol, Bristol, United Kingdom
  • Rebecca Nicole Evans
    University of Bristol, Bristol, United Kingdom
  • Alexandra Miere
    Hôpital Intercommunal de Créteil, Hôpital Henri Mondor, Université Paris Est Créteil, Créteil, France
  • Eric H Souied
    Hôpital Intercommunal de Créteil, Hôpital Henri Mondor, Université Paris Est Créteil, Créteil, France
  • Frank G Holz
    University of Bonn, Bonn, Germany
  • Tim U Krohne
    University of Bonn, Bonn, Germany
  • Tunde Peto
    Centre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom
  • Usha Chakravarthy
    Centre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom
  • Footnotes
    Commercial Relationships   Luping Wang, None; Alyson Muldrew, None; Barney Reeves, None; Rebecca Evans, None; Alexandra Miere, None; Eric Souied, None; Frank Holz, None; Tim Krohne, None; Tunde Peto, None; Usha Chakravarthy, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 2639. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Luping Wang, Alyson Muldrew, Barney Reeves, Rebecca Nicole Evans, Alexandra Miere, Eric H Souied, Frank G Holz, Tim U Krohne, Tunde Peto, Usha Chakravarthy; Fibrosis and HRM changes in treated neovascular age-related macular degeneration: findings from multimodal imaging of the IVAN clinical trial. Invest. Ophthalmol. Vis. Sci. 2020;61(7):2639.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Although anti-VEGF treatment results in improvements in retinal morphology and visual acuity, fibrosis occurs over time in the neovascular lesion and has recently been implicated in failure to effectively preserve visual acuity.To better understand evolution of fibrosis during anti-VEGF treatment, we explored its relationships with CNV subtype, the presence, severity and location of hyperreflective material (HRM) and tear of the retinal pigment epithelium by conducting a revised grading of the image repository in the IVAN trial.

Methods : In the subset of the IVAN trial (n = 135) participants who had spectral domain optical coherence tomography (SD-OCT) performed, we systematically classified the neovascular AMD lesion using both OCT modality and fluorescein angiographic features into specific nAMD subtypes. These were type 1 (occult), type 2 (classic), type 3 (retinal angiomatous proliferation), type 4 (polypoidal choroidal vasculopathy, PCV). Based on the SD-OCT we sub-classified HRM as subretinal non-fibrotic and fibrotic, subRPE non-fibrotic and fibrotic using both location and reflectivity to assign these characteristics. We measured the area of fibrosis on FA and height and width of the HRM on OCT.

Results : All patients had color fundus photograph (CFP), fluorescein angiography(FA)and SD-OCT at baseline and final visit at 24 months (M24). Among 135 eyes, the proportions of type 1, type 2, type 3 and type 4 CNV were 28.1% (n=38), 25.9% (n=35), 22.2% (n=30), and 23.0% (n=31), respectively. At baseline and M24, the mean height of HRM on OCT was 107.19± 104.15μm and 73.63±89.78μm. The mean width of HRM was 770.12 ± 845.26μm and 516.64± 686.86μm, respectively. The height and width of HRM were strongly correlated at baseline as well at final visit (Pearson’s r=0.837 and Pearson’s r=0.865, respectively), and the height and width of HRM were significant decreased at final visit 24 month compared to baseline (p=0.007 and p=0.010, respectively). The type 1 and type 4 CNV showed significant reduction in both height and width of HRM, however in type 2 and type 3, there was no reduction of HRM in either height or width.

Conclusions : In eyes with nAMD undergoing two years’ anti-VEGF treatment and follow up, the reduction of height and width of HRM was observed in various CNV subtypes, except type 2 and type 3.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×